To assess the impact of this activity on patient outcomes, we divided COAD and STAD patients into four groups: DCLK1Hi/CD8+Hi, DCLK1Hi/CD8+Lo, DCLK1Lo/CD8+Hi, and DCLK1Lo/CD8+Lo and performed Kaplan–Meier analysis. This evidence concerns the gene CD8A and colon adenocarcinoma.